News

Matregenix Awarded Third SBIR Contract from U.S. Air Force for Advancing Nanofibers in Ocular Trauma Applications

Written by Marketing team | Jun 1, 2024 9:26:02 AM

Mission Viejo, California - Matregenix Inc., a reputable name in nanofiber technology, proudly announces its selection by AFWERX for a Phase I SBIR contract, securing an award of $75,000. This latest achievement comes within three months of the company receiving two additional SBIR and STTR Phase I awards, totaling $185,000. Combined, these awards bring the total funding from the Department of the Air Force to $260,000 in 2024.

The new contract aims to advance the development of Matregenix’s MatriNova platform technology for soft tissue repair, specifically targeting the treatment of ocular trauma. These advancements are set to address some of the most pressing challenges faced by the Department of the Air Force (DAF).

The Air Force Research Laboratory and AFWERX have collaborated to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on May 15, 2024, Matregenix will start its journey to create and provide innovative capabilities including advanced Nanofiber Solutions, that will strengthen the national defense of the United States of America.

Sherif Soliman, CEO of Matregenix, states, "We're thrilled about the Air Force's continued interest in our technologies. Our extensive research and pre-clinical studies have yielded promising results in areas like Guided Bone Regeneration (GBR) and wound healing. We are particularly excited to advance the application of our MatriNova platform technology in ophthalmology. Our expertise in nanofiber manufacturing positions us ideally to advance these Technology Readiness Levels (TRL) and support the Air Force's mission."

Disclaimer: The views expressed are those of the company and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.

 About AFWERX

As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 325 military, civilian and contractor personnel at six hubs and sites, executing an annual $1.4 billion budget. Since 2019, AFWERX has executed 4,697 contracts worth more than $2.6 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: afwerx.com.